Stockscreener 앱 받기
57.20
4.27%
2.34
시간 외 거래:
56.33
-0.87
-1.52%
전일 마감가:
$54.86
열려 있는:
$54.9
하루 거래량:
2.50M
Relative Volume:
1.71
시가총액:
$3.96B
수익:
$1.50B
순이익/손실:
$427.61M
주가수익비율:
9.5175
EPS:
6.01
순현금흐름:
$423.98M
1주 성능:
-18.95%
1개월 성능:
-30.59%
6개월 성능:
-35.52%
1년 성능:
-41.19%
1일 변동 폭
$53.69
$57.21
1주일 범위
$47.25
$73.72
52주 변동 폭
$47.25
$118.21
Lantheus Holdings Inc Stock (LNTH) Company Profile
명칭
Lantheus Holdings Inc
전화
978 671-8001
주소
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
LNTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
57.20 | 3.59B | 1.50B | 427.61M | 423.98M | 6.01 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Goldman | Buy |
| 2024-09-03 | 개시 | Redburn Atlantic | Buy |
| 2024-07-10 | 재확인 | JMP Securities | Mkt Outperform |
| 2023-12-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-04 | 개시 | TD Cowen | Outperform |
| 2023-09-29 | 개시 | William Blair | Outperform |
| 2023-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2022-11-30 | 개시 | SVB Leerink | Outperform |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-05-09 | 개시 | B. Riley Securities | Buy |
| 2022-04-13 | 개시 | Truist | Buy |
| 2021-02-01 | 개시 | SVB Leerink | Outperform |
| 2020-06-29 | 재개 | Jefferies | Buy |
| 2019-08-16 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2017-11-02 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-11-08 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-23 | 재개 | Credit Suisse | Neutral |
| 2016-02-24 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-12-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2015-09-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2015-07-20 | 개시 | Credit Suisse | Outperform |
| 2015-07-20 | 개시 | Jefferies | Buy |
| 2015-07-20 | 개시 | RBC Capital Mkts | Outperform |
| 2015-07-20 | 개시 | Robert W. Baird | Outperform |
| 2015-07-20 | 개시 | Wells Fargo | Outperform |
모두보기
Lantheus Holdings Inc 주식(LNTH)의 최신 뉴스
Lantheus Holdings (LNTH) Dives 28.6% on Tempered Growth Outlook - MSN
Lantheus lowers 2025 revenue and EPS outlook, targets $1.475B–$1.51B revenue as pricing pressures persist - MSN
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2025 Earnings Call Transcript - Insider Monkey
Lantheus Holdings, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - uk.finance.yahoo.com
Lantheus Holdings Inc’s Mixed Earnings Call: Challenges and Strategic Advances - TipRanks
Best Mid Cap Stocks To ResearchAugust 6th - MarketBeat
LNTH: Competition Escalates in PSMA Imaging - Zacks Small Cap Research
Goldman Sachs lowers Lantheus stock price target to $110 on Pylarify concerns - Investing.com Australia
Goldman Sachs lowers Lantheus stock price target to $110 on Pylarify concerns By Investing.com - Investing.com South Africa
Did Lantheus Holdings, Inc. (LNTH) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Lantheus Holdings: Mizuho Downgrades to Outperform, PT to $70 from $120. - AInvest
Lantheus (LNTH) shares plummet 33.1% to $48.62. - AInvest
Lantheus Holdings 2025 Q2 Earnings Earnings Surge 26.9% Despite Revenue Dip - AInvest
Lantheus Holdings shares rise 1.79% premarket after announcing a $400 million share repurchase program. - AInvest
Lantheus stock price target lowered to $73 at JMP on pricing pressure - Investing.com Australia
Lantheus Holdings (LNTH) Announces US$400 Million Buyback Amid FDA and Earnings Updates - simplywall.st
Lantheus Holdings Reports Q2 2025 Results and Strategic Moves - TipRanks
Lantheus Shares Tumble 28.58% on $700M Trading Surge to 143rd Rank as FDA Progress and Strategic Moves Unfold - AInvest
Lantheus Holdings shares rise 1.18% after-hours after announcing a $400 million share repurchase program. - AInvest
FDA accepts Lantheus’ NDA for new Pylarify formulation - AuntMinnie
Lantheus Holdings: Q2 Earnings Snapshot - Chron
Why Lantheus (LNTH) Stock Is Falling Today - Yahoo Finance
Lantheus Shares Slide As Earnings And Outlook Fall Short - Finimize
Tranche Update on Lantheus Holdings, Inc.'s Equity Buyback Plan announced on November 20, 2024. - MarketScreener
Lantheus Holdings, Inc. announces an Equity Buyback for $400 million worth of its shares. - MarketScreener
Lantheus Q2 2025 slides: revenue falls 4.1%, company slashes full-year guidance - Investing.com Canada
Lantheus Holdings: Reassessing The Buy Thesis (NASDAQ:LNTH) - Seeking Alpha
Lantheus Holdings stock hits 52-week low at $51.75 By Investing.com - Investing.com Australia
Lantheus Holdings stock hits 52-week low at $51.75 - Investing.com
Earnings call transcript: Lantheus Q2 2025 misses forecasts, shares plunge - Investing.com India
Earnings call transcript: Lantheus Q2 2025 misses forecasts, shares plunge By Investing.com - Investing.com Nigeria
Lantheus Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantheus announces FDA review for new radioactive imaging agent - MSN
Lantheus Holdings Inc Q2 2025 Earnings: EPS Surges to $1.12, Bea - GuruFocus
Lantheus Holdings Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com
Lantheus Q2 Adjusted Earnings, Revenue Fall; Lowers 2025 Guidance; Shares Drop Pre-Bell - MarketScreener
Lantheus Holdings Plunges 22.21% on Missed Q2 Earnings - AInvest
Lantheus Announces FDA Acceptance of New Drug Application - TipRanks
Lantheus (NASDAQ:LNTH) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops 20.8% - Yahoo Finance
Lantheus Holdings, Inc. SEC 10-Q Report - TradingView
Why Lantheus Shares Are Taking a Hit - TipRanks
Lantheus stock slips on Q2 miss amid regulatory win (LNTH) - Seeking Alpha
FDA accepts Lantheus’ NDA for new PSMA PET imaging formulation By Investing.com - Investing.com Nigeria
FDA accepts Lantheus’ NDA for new PSMA PET imaging formulation - Investing.com India
Riley Reduces Lantheus Holdings (LNTH) PT to $109, Maintains Buy Rating - MSN
Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.57 per Share, vs. FactSet Est of $1.68 - MarketScreener
Lantheus Q2 rev. $378mln, adj. EPS $1.57, FDA okays new imaging agent, buys Life Molecular Imaging. - AInvest
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update - Stock Titan
Breakthrough: FDA Reviews New PSMA Imaging Formula That Could Help Thousands More Prostate Cancer Patients - Stock Titan
Lantheus Q2 Earnings Preview: Analyst Expectations and Potential Upside - AInvest
Lantheus (LNTH) Reports Q2: Everything You Need To Know Ahead Of Earnings - MSN
Lantheus Holdings Inc (LNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):